Video visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Dr. Leonid Metelitsa’s research focuses on understanding the role of Vα24-invariant natural killer T (NKT) cells in tumor immunity and translating this knowledge into NKT cell-based cancer immunotherapies. His group was the first to demonstrate that NKT cells localize to primary tumors in human patients and that presence of these cells at the tumor site is associated with favorable outcomes in the clinic (Metelitsa et al., JEM, 2004).
Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells.
Dr. Nuchtern's research program includes translational and clinical research on developing new treatments for pediatric solid tumors, particularly neuroblastoma. The primary focus in the laboratory is identifying new targets for neuroblastoma therapy; current research is directed toward identifying the pathways through which these molecules affect tumor progression. In addition to these translational studies, Dr. Nuchtern is involved in clinical research on neuroblastoma in infants.